Dyne Therapeutics (NASDAQ:DYN – Get Free Report) had its price objective increased by research analysts at Chardan Capital from $31.00 to $42.00 in a note issued to investors on Tuesday, Briefing.com reports. The firm currently has a “buy” rating on the stock. Chardan Capital’s price objective would suggest a potential upside of 18.71% from the […]